title: Recovery time in a case of gemfibrozil and simvastatin-associated rhabdomyolysis.
abstract: Simvastatin is a cholesterol-lowering medication heavily prescribed to treat and prevent vascular disease. Despite widespread use, cases of simvastatin-induced rhabdomyolysis are rare. Little information is available regarding the recovery period for a patient who has experienced drug-induced rhabdomyolysis. We present a case involving a patient with multiple risk factors (advanced age, high-dose simvastatin therapy, concomitant nonsteroidal anti-inflammatory medication, and concomitant gemfibrozil therapy) and highlight his recovery course.
authors: Department of Pharmacy Practice, Family and Community Medicine, Area Health Education Center-Northeast, University of Arkansas for Medical Sciences, Jonesboro, AR, USA. dcummins@ahecne.uams.edu
authors: Dosha
authors: D
authors: Cummins
authors: Michael
authors: M
authors: Mackey
authors: Erica
authors: E
authors: Baker
mesh_terms: D058186:Acute Kidney Injury / Q000209:etiology*; D000369:Aged, 80 and over; D003402:Creatine Kinase / Q000097:blood; D003404:Creatinine / Q000097:blood; D004359:Drug Therapy, Combination; D015248:Gemfibrozil / Q000009:adverse effects*; D006801:Humans; D000960:Hypolipidemic Agents / Q000009:adverse effects*; D008297:Male; D012206:Rhabdomyolysis / Q000097:blood / Q000139:chemically induced*; D019821:Simvastatin / Q000009:adverse effects*
chemical_list: D000960:Hypolipidemic Agents; D019821:Simvastatin; D003404:Creatinine; D003402:Creatine Kinase; D015248:Gemfibrozil